March 14 (Reuters) - ProMIS Neurosciences Inc:
* PROMIS NEUROSCIENCES ANNOUNCES FISCAL YEAR 2017 ANNUAL RESULTS
* PROMIS NEUROSCIENCES INC - TOP PRIORITY FOR 2018 TO CONTINUE TO PROGRESS DEVELOPMENT OF PMN310 FOR CLINICAL TRIAL INITIATION IN 2019
* PROMIS NEUROSCIENCES - IN 2018, WILL CONTINUE TO EXPAND PROGRAM TARGETING TDP43 IN ALS AND FTD AND ITS ALPHA-SYNUCLEIN PROGRAM FOR PD Source text for Eikon: Further company coverage:
